BACK TO CONGRESSES

AACR IO 2026

Feb 18 - 21, 2026 | Los Angeles, CA

The agents listed below are currently under investigation. Their safety and efficacy have not been established.

Poster
Antitumor and Immunomodulatory Activity of ARV-6723, a PROTAC HPK1 Degrader, Across High- and Low-Immunogenic Solid Tumors

AC Van Acker et al.

VIEW MATERIAL